Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.
Saved in:
| Title: | Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. |
|---|---|
| Authors: | Guijosa A; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Ramirez-Gamero A; Department of Medicine, Roger Williams Medical Center, Providence, RI., Sarosiek S; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Branagan AR; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA., von Keudell G; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA., Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. |
| Source: | Blood advances [Blood Adv] 2025 Sep 23; Vol. 9 (18), pp. 4705-4715. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
